<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944658</url>
  </required_header>
  <id_info>
    <org_study_id>112008</org_study_id>
    <secondary_id>2008-004229-40</secondary_id>
    <nct_id>NCT00944658</nct_id>
  </id_info>
  <brief_title>Spondylitis Trial of Apremilast for Better Rheumatic Therapy</brief_title>
  <acronym>START</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of apremilast in AS as measured by improvement in&#xD;
      patients' signs and symptoms of the disease and changes in imaging. Additionally the safety&#xD;
      and tolerability of apremilast in AS will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Presently, there are very few treatments available which affect the progression of the&#xD;
      disease in the spine. The only proven treatment is the use of drugs inhibiting tumour&#xD;
      necrosis factor alpha (TNF). However, there are limitations with this treatment in that it&#xD;
      needs to be administered via an injection and is also very expensive. Therefore it is&#xD;
      necessary to develop new therapeutic agents for this condition.&#xD;
&#xD;
      Apremilast (the study drug) is an oral tablet which has been shown to inhibit TNF production&#xD;
      in a mouse model of inflammation. It has also been used in clinical trials for asthma and&#xD;
      psoriasis in humans with good affect and tolerability.&#xD;
&#xD;
      These studies were funded by Celgene Corporation and they will be funding this study.&#xD;
&#xD;
      The patients will be recruited from hospitals by Consultant referral. The patients will have&#xD;
      had AS for at least 2 years and their symptoms will have been uncontrolled on conventional&#xD;
      non-steroidal anti-inflammatory drugs such as ibuprofen. Patients will be randomised to&#xD;
      either receive apremilast or a placebo and treated over a period of 12 weeks. They will then&#xD;
      be followed up for 28 days after the treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of Apremilast on the Signs and Symptoms of AS, Night Pain From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>This endpoint the night time pain score change was recorded by questionnaire to evaluate the Apremilast effect on symptom, higher reduction better improvement.&#xD;
scale is 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Apremilast in Patients With AS, Changes in BASFI Score</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Bath Ankylosing Spondylitis Functional Index (BASFI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Safety and Tolerability of Apremilast in AS, Number of Participants With Adverse Events</measure>
    <time_frame>16 weeks</time_frame>
    <description>To evaluate the safety and tolerability of Apremilast in AS, the investigator recorded the incidence of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo twice a day for 12 weeks, 4 weeks follow up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg twice a day for 12 weeks, 4 weeks follow up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
    <arm_group_label>Apremilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (sugar pill)</intervention_name>
    <description>twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent to participate in this trial&#xD;
&#xD;
          -  Diagnosis of ankylosing spondylitis as defined by the modified New York criteria&#xD;
             (1984) as follows:&#xD;
&#xD;
               1. a history of inflammatory back pain;&#xD;
&#xD;
               2. limitation of motion of the lumbar spine in both the sagittal and frontal planes;&#xD;
&#xD;
               3. limited chest expansion, relative to standard values for age and sex;&#xD;
&#xD;
               4. definite radiographic / imaging evidence of sacroiliitis and/or spinal&#xD;
                  inflammation&#xD;
&#xD;
          -  Patients must have daily spinal pain and stiffness for at least 2 weeks prior to&#xD;
             randomization. This is defined by having a score of &gt;1 on questions #2 and #5 of the&#xD;
             BASDAI score for the 2 weeks prior to randomization.&#xD;
&#xD;
          -  Patients receiving NSAIDS and/or COX-2 inhibitors must be on stable doses for at least&#xD;
             2 weeks prior to randomization.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Male and female patients, who are not surgically sterile or postmenopausal, must use&#xD;
             reliable methods of birth control for the duration of the study. Males must agree to&#xD;
             use barrier contraception for 3 months following the end of the trial.&#xD;
&#xD;
          -  Women of childbearing potential, not surgically sterile or postmenopausal, must have a&#xD;
             negative serum beta HCG.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of DMARDs (methotrexate, d-penicillamine, sulfasalazine, azathioprine,&#xD;
             hydroxychloroquine, or gold) within 8 weeks of randomization.&#xD;
&#xD;
          -  Use of systemic corticosteroids within 4 weeks of randomization&#xD;
&#xD;
          -  Use of intravenous or intra-articular corticosteroids within 4 weeks of randomization&#xD;
&#xD;
          -  Use of TNF alpha blockers (eg, infliximab, adalimumab) or etanercept as follows:&#xD;
&#xD;
        Compound PK Exclusion period Etanercept T ½ = 102 hrs = 4.25 days 4 weeks Adalimumab T ½ 2&#xD;
        wks; 5 half lives 10 weeks 10 weeks Infliximab T ½ 7.7-9.5 d 12 weeks 8 weeks after&#xD;
        maintenance dose median infx conc 0.5-6 mcg/ml&#xD;
&#xD;
          -  Therapy with an investigational agent within 30 days of randomization or 5 half-lives&#xD;
             (pharmacokinetic or pharmacodynamic), which ever is longer&#xD;
&#xD;
          -  Known HIV or hepatitis B or C infection&#xD;
&#xD;
          -  Exclusion of tuberculosis (TB)&#xD;
&#xD;
               -  History of active Mycobacterium tuberculosis infection (any subspecies) within 3&#xD;
                  years prior to the screening visit. Infections that occurred &gt; 3 years prior to&#xD;
                  entry must have been effectively treated.&#xD;
&#xD;
               -  History of incompletely treated latent Mycobacterium tuberculosis infection (as&#xD;
                  indicated by a positive Purified Protein Derivative [PPD] skin test)&#xD;
&#xD;
               -  Clinically significant abnormality on chest x-ray (CXR) if mantoux &gt;5mm or&#xD;
                  ELISPOT positive&#xD;
&#xD;
          -  History of other rheumatic autoimmune diseases (eg, systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, etc.)&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Any condition, in the investigator's opinion, which places the patient at an undue&#xD;
             risk by participating in the study.&#xD;
&#xD;
          -  Contraindication to MRI and other MRI exclusions following local centre guidelines&#xD;
             (Appendix H)&#xD;
&#xD;
          -  An estimated glomerular filtration rate (eGFR) of &lt; 60 ml/min (because of the small&#xD;
             risk of nephrogenic sclerosing fibrosis with gadolinium intravenous contrast), if&#xD;
             patient is to have MRI with gadolinium contrast .&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL&#xD;
&#xD;
          -  White blood cell (WBC) count &lt; 3000 /μL (≥ 3.0 X 109/L) and ≥ 14,000/μL (≥ 20 X 109/L)&#xD;
&#xD;
          -  Neutrophils &lt; 1500 /μL (&lt; 1.5 X 109/L)&#xD;
&#xD;
          -  Platelets &lt; 100,000 /μL (&lt; 100 X 109/L)&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 mg/dL (&gt; 132.6 μmol/L)&#xD;
&#xD;
          -  Total bilirubin &gt; 2.0 mg/dL&#xD;
&#xD;
          -  Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and&#xD;
             alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) &gt; 1.5x upper&#xD;
             limit of normal (ULN)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Taylor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Kennedy Institute Clinical Trials Unit, 4 West, Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, Paterson E, Chowdhury M, McClinton C, Taylor PC. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013 Sep 1;72(9):1475-80. doi: 10.1136/annrheumdis-2012-201915. Epub 2012 Sep 14.</citation>
    <PMID>22984171</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 20, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <results_first_submitted>August 22, 2019</results_first_submitted>
  <results_first_submitted_qc>November 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 6, 2019</results_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing spondylitis</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
        </group>
        <group group_id="P2">
          <title>Apremilast</title>
          <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
        </group>
        <group group_id="B2">
          <title>Apremilast</title>
          <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.21" spread="13.3"/>
                    <measurement group_id="B2" value="44.88" spread="11.1"/>
                    <measurement group_id="B3" value="42.95" spread="11.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
          <description>The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue, 0 being no problem and 10 being the worst problem</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.36" spread="1.75"/>
                    <measurement group_id="B2" value="4.79" spread="2.16"/>
                    <measurement group_id="B3" value="4.57" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bath Ankylosing Spondylitis Functional Index (BASFI)</title>
          <description>A visual analogue scale with 0 being &quot;easy&quot; and 10 &quot;impossible&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.19" spread="2.2"/>
                    <measurement group_id="B2" value="4.55" spread="2.42"/>
                    <measurement group_id="B3" value="3.87" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CRP C-reactive protein</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                    <count group_id="B2" value="17"/>
                    <count group_id="B3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.24" spread="2.56"/>
                    <measurement group_id="B2" value="11.37" spread="12.12"/>
                    <measurement group_id="B3" value="8.8" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline</title>
        <description>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Apremilast in Patients With AS, Changes in BASDAI Score From Baseline</title>
          <description>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="1.47"/>
                    <measurement group_id="O2" value="-1.59" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.139</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes of Apremilast on the Signs and Symptoms of AS, Night Pain From Baseline</title>
        <description>This endpoint the night time pain score change was recorded by questionnaire to evaluate the Apremilast effect on symptom, higher reduction better improvement.&#xD;
scale is 0-10</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Apremilast on the Signs and Symptoms of AS, Night Pain From Baseline</title>
          <description>This endpoint the night time pain score change was recorded by questionnaire to evaluate the Apremilast effect on symptom, higher reduction better improvement.&#xD;
scale is 0-10</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="2.75"/>
                    <measurement group_id="O2" value="-0.81" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Apremilast in Patients With AS, Changes in BASFI Score</title>
        <description>Bath Ankylosing Spondylitis Functional Index (BASFI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Apremilast in Patients With AS, Changes in BASFI Score</title>
          <description>Bath Ankylosing Spondylitis Functional Index (BASFI), 0 - 10 score, higher reduction in the scores suggest better suboptimal control of disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="1.61"/>
                    <measurement group_id="O2" value="-1.74" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>ANCOVA</method>
            <method_desc>Rank Ancova</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Safety and Tolerability of Apremilast in AS, Number of Participants With Adverse Events</title>
        <description>To evaluate the safety and tolerability of Apremilast in AS, the investigator recorded the incidence of adverse events.</description>
        <time_frame>16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
          </group>
          <group group_id="O2">
            <title>Apremilast</title>
            <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Safety and Tolerability of Apremilast in AS, Number of Participants With Adverse Events</title>
          <description>To evaluate the safety and tolerability of Apremilast in AS, the investigator recorded the incidence of adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo twice a day for 12 weeks, 4 weeks follow up&#xD;
Placebo (sugar pill): twice a day</description>
        </group>
        <group group_id="E2">
          <title>Apremilast</title>
          <description>30 mg twice a day for 12 weeks, 4 weeks follow up&#xD;
Apremilast: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>raised serum amylase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flatulance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoe</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>It was most likely underpowered to detect a signiﬁcant beneﬁt of Apremilast in AS patients because no information on an effect size was available to aid in the study design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Taylor</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0) 2075941872</phone>
      <email>jrco@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

